The old model for medicine is structurally broken. New molecules are discovered in the lab faster than ever, but then enter years-long trials that capture only a snapshot of their effect on a sample population. We still treat patients based on these population averages, when in reality every person's health is n-of-1.
We aim to fix that by building observability into individual treatment responses, so AI can form a mechanistic understanding of how therapies behave in the patients who receive them. That sharpens the drugs still in development, and across the drug lifecycle gives every patient more precise care.
A therapy only matters once it works in the real lives of the people taking it. Today, the industry still runs on trial snapshots, historic data that AI cannot interpret, and outdated models and every party pays for the gap: Drug developers fight to differentiate in crowded indications, where rival drugs look identical across a wide patient set. Regulators demand granular tolerability data to see the real picture. Patients walk into appointments better informed than the protocols treating them, and lose trust in the system.
We're building toward a new paradigm: treatments that match the person taking them, based on a deep understanding of the biology behind each response.
If this resonates with you, we invite you to partner with us. Our team moves fast, thinks deeply, and believes that rigorous, creative collaboration can solve the most meaningful problems in healthcare.